We are live on ! Find out more
TRV

Third Rock Ventures Portfolio holdings

AUM $1.07B
1-Year Est. Return 170.23%
This Fund
S&P 500
This Quarter Est. Return
+36.02%
1 Year Est. Return
+170.23%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$961M
AUM Growth
+$23.2M
Cap. Flow
-$125M
Cap. Flow %
-13.02%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$211M

Top Sells

Rank Stock Value
1
FMI
Foundation Medicine, Inc.
FMI
+$237M
2
SAGE
Sage Therapeutics
SAGE
+$64.3M
3
LRMR icon
Larimar Therapeutics
LRMR
+$34.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
1
DELISTED
Sage Therapeutics
SAGE
$640M 66.66%
8,773,073
-1,000,000
-10% -$64.3M
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$196M 20.38%
+7,393,059
New +$211M
LRMR icon
3
Larimar Therapeutics
LRMR
$398M
$111M 11.54%
266,837
-83,333
-24% -$34.9M
CARM
4
DELISTED
Carisma Therapeutics
CARM
$13.7M 1.42%
242,080
– –
FMI
5
DELISTED
Foundation Medicine, Inc.
FMI
– –
-4,927,234
Closed -$237M

Similar funds

AH
Achievement Holdings Chicago, Illinois $1.2B AUM 9.2% 1-Year Est. Return
GHF
Good Harbor Financial Barrington, Illinois $916M AUM 5.96% 1-Year Est. Return
CWA
Constellation Wealth Advisors New York $903M AUM 2.38% 1-Year Est. Return
RI
Relational Investors San Diego, California $840M AUM 0.57% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return
F
FutureAdvisor San Francisco, California $617M AUM 6.57% 1-Year Est. Return
MCC
Mid Continent Capital Chicago, Illinois $1.54B AUM 0.7% 1-Year Est. Return
OA
OFI Advisors Philadelphia, Pennsylvania $1.55B AUM 1.44% 1-Year Est. Return

Third Rock Ventures's Q2 2015 Portfolio in Review

As of Q2 2015, Third Rock Ventures held 5 positions worth $961M, up 2.5% from $938M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Third Rock Ventures withdrew a net $125M in Q2 2015, closing 1 position and reducing 2 holdings. Its most notable exit was Foundation Medicine, Inc., an estimated $237M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Third Rock Ventures opened a new position in Blueprint Medicines worth $196M.

  • Third Rock Ventures's largest Q2 2015 buy was Blueprint Medicines: 7,393,059 shares worth $196M.
  • Third Rock Ventures's biggest Q2 2015 reduction was Sage Therapeutics, cutting an estimated $64.3M.
  • Third Rock Ventures fully exited Foundation Medicine, Inc. in Q2 2015, selling an estimated $237M.
  • Third Rock Ventures's ten largest holdings make up 100% of its $961M portfolio in Q2 2015.
  • Third Rock Ventures opened 1 new position and closed 1 in Q2 2015.
  • Third Rock Ventures's portfolio value rose 2.5% quarter-over-quarter to $961M.

Based on Third Rock Ventures's 13F filing for Q2 2015, filed 30 Jul 2015.